BARTALUCCI, NICCOLO'
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.944
EU - Europa 2.948
AS - Asia 1.935
SA - Sud America 228
AF - Africa 47
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 2
Totale 9.126
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.901
RU - Federazione Russa 920
PL - Polonia 630
IT - Italia 594
SG - Singapore 564
CN - Cina 533
HK - Hong Kong 271
VN - Vietnam 184
IE - Irlanda 183
BR - Brasile 179
KR - Corea 160
SE - Svezia 151
DE - Germania 99
FR - Francia 86
FI - Finlandia 76
IN - India 72
GB - Regno Unito 68
CH - Svizzera 58
JO - Giordania 26
CA - Canada 25
AU - Australia 22
BD - Bangladesh 20
ID - Indonesia 20
JP - Giappone 19
NL - Olanda 18
AR - Argentina 15
ES - Italia 15
CI - Costa d'Avorio 13
MX - Messico 13
NG - Nigeria 13
UA - Ucraina 11
BE - Belgio 10
TR - Turchia 10
IQ - Iraq 8
PY - Paraguay 8
AT - Austria 7
PH - Filippine 7
AE - Emirati Arabi Uniti 6
CL - Cile 6
PK - Pakistan 6
UZ - Uzbekistan 6
VE - Venezuela 6
EC - Ecuador 5
KZ - Kazakistan 5
SA - Arabia Saudita 5
BJ - Benin 3
CO - Colombia 3
DZ - Algeria 3
GR - Grecia 3
MA - Marocco 3
ZA - Sudafrica 3
AZ - Azerbaigian 2
BO - Bolivia 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
HN - Honduras 2
HU - Ungheria 2
KE - Kenya 2
KH - Cambogia 2
LB - Libano 2
LT - Lituania 2
LV - Lettonia 2
PE - Perù 2
TN - Tunisia 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
BY - Bielorussia 1
CG - Congo 1
CY - Cipro 1
EE - Estonia 1
GA - Gabon 1
HR - Croazia 1
JM - Giamaica 1
KW - Kuwait 1
LK - Sri Lanka 1
MT - Malta 1
MU - Mauritius 1
MY - Malesia 1
NO - Norvegia 1
PA - Panama 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PT - Portogallo 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
TG - Togo 1
TH - Thailandia 1
TW - Taiwan 1
YT - Mayotte 1
Totale 9.126
Salva come PNG Salva come JPEG
Città #
Santa Clara 865
Warsaw 628
Ashburn 541
Singapore 403
Fairfield 289
Hong Kong 230
Dublin 183
Chandler 163
Seoul 159
San Jose 149
Woodbridge 141
Seattle 140
Beijing 123
Houston 115
Hefei 108
Cambridge 106
Wilmington 96
Dallas 95
Florence 93
Milan 89
Ann Arbor 88
Buffalo 66
Los Angeles 62
Ho Chi Minh City 61
Altamura 59
Lawrence 59
Bern 58
The Dalles 46
Lauterbourg 45
Hanoi 44
Princeton 43
Moscow 42
Rome 42
Council Bluffs 39
Munich 39
Mumbai 37
New York 34
Boston 30
Helsinki 29
Kent 27
Shanghai 24
Bremen 23
Paris 23
Turku 22
Melbourne 20
Tokyo 19
Medford 18
Clifton 17
São Paulo 17
Jakarta 16
Orem 16
Boardman 15
London 15
San Diego 15
Abidjan 13
Abuja 13
Denver 13
Frankfurt am Main 13
Dong Ket 12
Turin 12
Chicago 11
Da Nang 11
Jacksonville 11
Brussels 10
Falls Church 10
Naples 10
Phoenix 10
Redondo Beach 10
Elk Grove Village 9
Lappeenranta 9
Amsterdam 8
Bologna 8
Chennai 8
Indianapolis 8
Palermo 8
Tianjin 8
West Jordan 8
Brooklyn 7
Mexico City 7
Montreal 7
Cagliari 6
Figino 6
Guangzhou 6
Manchester 6
Norwalk 6
Pian di Scò 6
Porto Alegre 6
Pune 6
Tashkent 6
Toronto 6
Atlanta 5
Bengaluru 5
Haiphong 5
Hillsboro 5
Rignano sull'Arno 5
Vienna 5
Yubileyny 5
Abu Dhabi 4
Brescia 4
Castel Maggiore 4
Totale 6.287
Salva come PNG Salva come JPEG
Nome #
Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial 342
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. 332
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. 319
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera. 284
Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/ CIP2A axis 262
Differentiation of crescent-forming kidney progenitor cells into podocytes attenuates severe glomerulonephritis in mice 261
Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants 259
Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation 225
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) 224
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: Pathogenetic insight and diagnostic value 216
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis 208
THIRD GENERATION SEQUENCING OF NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA: IMPLICATIONS FOR PROGNOSIS 199
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. 197
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea 196
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 194
Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. 194
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients 188
Nano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data 186
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis 180
Role of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis 172
Long Reads, Short Time: Feasibility of Prenatal Sample Karyotyping by Nanopore Genome Sequencing 171
RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features 171
Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis 168
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis 167
Peripheral nerve resident macrophages and schwann cells mediate cancer-induced pain A C 167
Studio della via di segnalazione Akt/mTOR nelle Neoplasie Mieloproliferative Croniche 166
Novel insights into myelofibrosis pathophysiology and treatment 165
Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs 165
Preclinical models for drug selection in myeloproliferative neoplasms. 163
Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model 156
The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis 155
Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms. 153
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms 153
Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2 150
Familial dominant epilepsy and mild pachgyria associated with a constitutional LIS1 mutation 149
JAK PI3K/mTOR COMBINATION THERAPY 145
NANOR: A user-friendly R package to analyze and compare nanopore sequencing data 139
Resolving complex structural variants via nanopore sequencing 138
No role for CXCL12-G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia. 136
Rationale for combination therapies in myelofibrosis 136
Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms 135
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates 133
A blood drop through the pore: nanopore sequencing in hematology 133
Philadelphia-negative myeloproliferative neoplasms: From origins to new perspectives 130
Targeting the PI3K pathway in myeloproliferative neoplasms 125
A novel approach for highly sensitive and rapid identification of HMGA2 submicroscopic deletions in myeloproliferative neoplasms 114
Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms. 113
Chromosome 9p trisomy increases stem cells clonogenic potential and fosters T-cell exhaustion in JAK2-mutant myeloproliferative neoplasms 105
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. 98
Polycythemia vera: the current status of preclinical models and therapeutic targets 95
Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells 87
CD44 Participates to Extramedullary Haematopoiesis Onset by Mediating the Interplay Between Monocytes and Haematopoietic Stem Cells in Myelofibrosis 69
Proteomic screening identifies PF4/Cxcl4 as a critical driver of myelofibrosis 47
Correction: A novel approach for highly sensitive and rapid identification of HMGA2 submicroscopic deletions in myeloproliferative neoplasms 34
Clinical Experience With Venetoclax-Based Combinations for Relapsed/Refractory or MRD-Positive NPM1-Mutated Acute Myeloid Leukemia. 27
Genomic structural variations contribute to inform prognosis in patients with cytogenetically normal acute myeloid leukemia 9
A Novel, Ruxolitinib-Sensitive, CCDC6::JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera-Like, Myeloproliferative Neoplasm 7
Totale 9.212
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.906
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.906
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022304 8 10 40 7 9 18 5 27 24 15 54 87
2022/2023850 70 177 48 59 44 137 109 51 64 6 18 67
2023/2024408 17 34 55 20 43 54 6 81 12 30 36 20
2024/20252.612 77 247 159 415 685 375 80 130 111 79 127 127
2025/20263.139 353 429 300 253 336 112 373 145 204 201 107 326
Totale 9.212